The platform, named RadGLO, extracts genetic insights from MRI images. Doctors can now plan personalized treatments for glioma patients without surgery. The study was published in Precision Oncology in October 2025.

The team also introduced RaSPr (Radiomic Survival Predictor). It sorts patients into high-risk and low-risk groups based on MRI features. Doctors can now predict tumour aggressiveness, treatment response, and survival outcomes faster and more safely.

RadGLO links MRI features to 20,000 genes, providing insights into the tumour’s molecular profile. Doctors upload scans, receive automated risk predictions, and access genetic correlations. The platform enables accurate, personalized treatment planning. The research team included Kavita Kundal, Dr. K. Divya Rani, Vinodini D, Dr. Neeraj Kumar, and Dr. Rahul Kumar.

The post IIT Hyderabad Develops AI Tool for Brain Tumour Diagnosis appeared first on India Podcast.

AdFalciVax specifically targets Plasmodium falciparum, the deadliest malaria parasite. It not only protects individuals from infection but also prevents transmission through mosquitoes, breaking the disease cycle. Health experts believe this vaccine could be a turning point in India’s fight against malaria.

Pre-clinical studies revealed strong immune responses and long-lasting protection. Unlike traditional vaccines, AdFalciVax offers broader coverage and remains stable at room temperature for up to nine months. This feature makes it easier to transport and store in remote areas where refrigeration is often unavailable.

The vaccine is produced using the safe bacterium Lactococcus lactis. For nationwide production, ICMR has licensed five companies: Indian Immunologicals Limited, TexInvention Lifecare, Panacea Biotech, Biological E Limited, and Zydus Lifesciences. The first batch is expected to be available by the end of this year, raising hopes for large-scale malaria control.

The post ICMR Develops Indigenous Malaria Vaccine AdFalciVax appeared first on India Podcast.